Unusual anti-angiogenic effect of combined hormonal blockade.
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000813:Anilides / Q000008:administration & dosage* / Q000009:adverse effects; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects; D002196:Capillaries / Q000187:drug effects; D017024:Chemotherapy, Adjuvant; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009570:Nitriles; D011471:Prostatic Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D012867:Skin / Q000098:blood supply*; D013684:Telangiectasis / Q000188:drug therapy*; D014105:Tosyl Compounds; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; D018120:Finasteride; C053541:bicalutamide; D016729:Leuprolide